Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
4
|
| pubmed:dateCreated |
1993-5-5
|
| pubmed:abstractText |
A comparative study of three different high-dose regimens of interferon-alpha-2b (IFN) was conducted in patients with chronic hepatitis C to determine which was better at obtaining a sustained remission. A total of 126 patients were assigned randomly to one of three groups: group A was given 10 million international units (MIU) of IFN six times a week for eight weeks; group B was given 10 MIU IFN six times a week for four weeks followed by three times a week for an additional eight weeks; group C was given 10 MIU IFN six times a week for two weeks followed by three times a week for 12 weeks. The total dose administered to each group was 480 MIU/patient. Only the dosing schedule varied among the three groups. Among 98 efficacy-evaluable patients, a sustained alanine aminotransferase (ALT) response, defined as persistent normalization of the ALT for greater than six months after the termination of treatment, was achieved in 21.2% (7/33) of group A, 42.3% (11/26) of group B, and 54.5% (18/33) of group C patients. Similarly, a sustained loss of measurable serum hepatitis C virus RNA was observed in 28.6% (8/28) of group A, 40.9% (9/22) of group B, and 48.3% (14/29) of group C patients. Based upon these data, it can be concluded that 10 MIU of IFN administered six days a week for two weeks followed by three times a week for an additional 12 weeks produces the highest rate of both biochemical and virological responses to IFN therapy in patients with chronic HCV.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/2',5'-Oligoadenylate Synthetase,
http://linkedlifedata.com/resource/pubmed/chemical/Alanine Transaminase,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies,
http://linkedlifedata.com/resource/pubmed/chemical/Aspartate Aminotransferases,
http://linkedlifedata.com/resource/pubmed/chemical/Interferon-alpha,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Viral,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/interferon alfa-2b
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0163-2116
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
38
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
612-8
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:8384980-2',5'-Oligoadenylate Synthetase,
pubmed-meshheading:8384980-Alanine Transaminase,
pubmed-meshheading:8384980-Analysis of Variance,
pubmed-meshheading:8384980-Antibodies,
pubmed-meshheading:8384980-Aspartate Aminotransferases,
pubmed-meshheading:8384980-Chi-Square Distribution,
pubmed-meshheading:8384980-Chronic Disease,
pubmed-meshheading:8384980-Female,
pubmed-meshheading:8384980-Hepacivirus,
pubmed-meshheading:8384980-Hepatitis C,
pubmed-meshheading:8384980-Humans,
pubmed-meshheading:8384980-Interferon-alpha,
pubmed-meshheading:8384980-Japan,
pubmed-meshheading:8384980-Male,
pubmed-meshheading:8384980-Middle Aged,
pubmed-meshheading:8384980-RNA, Viral,
pubmed-meshheading:8384980-Recombinant Proteins,
pubmed-meshheading:8384980-Regression Analysis,
pubmed-meshheading:8384980-Retrospective Studies,
pubmed-meshheading:8384980-Time Factors
|
| pubmed:year |
1993
|
| pubmed:articleTitle |
Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study.
|
| pubmed:affiliation |
Institute of Medical Science, St. Marianna University Medical School, Kawasaki, Japan.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Multicenter Study
|